SAB Biotherapeutics, a Sioux Falls, S.D.-based clinical-stage biopharmaceutical development company, received a Small Business Innovation Research (SBIR) Grant for up to $1.42M.
The National Institutes of Health (NIH) provided the award for the production and preclinical testing of SAB’s novel antibody therapeutic targeting influenza viruses, in collaboration with the University of South Dakota (USD) Sanford School of Medicine.
The project was initiated through the BioSNTR, a distributed research initiative that facilitates academic and industry research collaborations to advance biotechnology and commercialize innovations.
The treatment is produced from the company’s DiversitAb™ Platform leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce fully human antibodies (immunoglobulin G) in response to an antigen–in this case influenza viruses.
Led by Eddie Sullivan, Ph.D., President and CEO, SAB Biotherapeutics is a clinical stage, biopharmaceutical development company focused on science and manufacturing of antibody therapeutics. Utilizing advanced antibody science, SAB is delivering a large-scale platform to create immunoglobulins, which holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.